Sarepta Therapeutics (NASDAQ:SRPT) Raised to Hold at Wall Street Zen

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other research analysts have also issued research reports about the company. Guggenheim reduced their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Barclays assumed coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, January 27th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $33.56.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $16.76 on Friday. The company’s fifty day moving average price is $20.43 and its 200-day moving average price is $20.22. The stock has a market cap of $1.76 billion, a PE ratio of -1.99, a price-to-earnings-growth ratio of 0.27 and a beta of 0.42. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $108.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million for the quarter, compared to analysts’ expectations of $390.95 million. During the same period last year, the business earned $1.90 earnings per share. The company’s revenue was down 32.7% on a year-over-year basis. On average, equities analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics in the third quarter worth about $25,000. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $25,000. Ancora Advisors LLC raised its position in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $33,000. Finally, Allworth Financial LP increased its stake in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,721 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.